Dna, D(3'-Amino-3'-Deoxy-P-Thio)(T-A-G-G-G-T-T-A-G-A-C-A-A), 5'-(O-(2-Hydroxy-3-((1-Oxohexadecyl)Amino)Propyl) Hydrogen Phosphorothioate)
Rhabdomyosarcoma
Children's Oncology Groupnucleic_acidPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
59 Active assets in the Rhabdomyosarcoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ipilimumab Children's National Research Institute | Phase 2 | BB |
Calcium Phosphate Children's Oncology Group | Phase 3 | BB |
Oxaliplatin National Cancer Institute (NCI) | Phase 2 | BB |
Irinotecan Milton S. Hershey Medical Center | Phase 2 | BB |
Cixutumumab National Cancer Institute (NCI) | Phase 2 | B |
View all 50 →
Same molecule, other indications
Dna, D(3'-Amino-3'-Deoxy-P-Thio)(T-A-G-G-G-T-T-A-G-A-C-A-A), 5'-(O-(2-Hydroxy-3-((1-Oxohexadecyl)Amino)Propyl) Hydrogen Phosphorothioate) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →